Drug Patents owned by Allergan
1. List of Acular Ls drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8008338 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216167 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 3 months from now) | |
| US8541463 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 3 months from now) | |
| US8648107 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 3 months from now) | |
| US8906950 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 3 months from now) | |
| US8946281 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 3 months from now) | |
| US8207215 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 3 months from now) | |
| US8377982 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 3 months from now) | |
|
US8207215
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 9 months from now) | |
|
US8541463
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 9 months from now) | |
|
US8377982
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(1 year, 9 months from now) | |
|
US8008338
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(4 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating or preventing ocular pain in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
2. List of Acuvail drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7842714 | ALLERGAN | Ketorolac tromethamine compositions for treating ocular pain |
Aug, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8992952 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(1 year, 6 months from now) | |
| US8512717 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(5 years from now) | |
| US9192571 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(5 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
3. List of Alphagan P drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9295641
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 21 days ago) | |
|
US9687443
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 21 days ago) | |
|
US6562873
(Pediatric) | ALLERGAN | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(1 year, 21 days ago) | |
|
US6627210
(Pediatric) | ALLERGAN | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(1 year, 13 days ago) | |
|
US6673337
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 5 days ago) | |
|
US6641834
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 3 days ago) | |
| US8858961 | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(6 months from now) | |
|
US8858961
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(1 year, 30 days from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 19 August, 2005
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
4. List of Avycaz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(2 years from now) | |
| US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(8 years from now) | |
| US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(3 years from now) | |
| US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
| Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally effective amount of avibactam sodium; A method of treating bacterial infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pnenumonia (habp/vabp) patients comprising administering a bactericidally effective amount of avibactam sodium; Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
5. List of Byvalson drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803838 | ALLERGAN | Compositions comprising nebivolol |
Aug, 2026
(3 years from now) | |
| US7838552 | ALLERGAN | Compositions comprising nebivolol |
Oct, 2027
(4 years from now) | |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
6. List of Canasa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8217083 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(5 years from now) | |
| US8436051 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(5 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 January, 2001
Treatment: NA
Dosage: SUPPOSITORY;RECTAL
7. List of Combigan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7642258 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320976 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US9474751 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US7030149 | ALLERGAN | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US9907802 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US8748425 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US8354409 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US9907801 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US9770453 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US8133890 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US7323463 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(12 days ago) | |
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of combigan in the affected eye twice daily; Reduction of elevated intraocular pressure; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy to brimonidine 0.2% tid; Reduction of intraocular pressure in patients with elevated intraocular pressure or glaucoma; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy, and a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop
Dosage: SOLUTION/DROPS;OPHTHALMIC
8. List of Dalvance drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143212 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(9 months from now) | |
| US7119061 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(9 months from now) | |
| US7115564 | ALLERGAN | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(9 months from now) | |
| US6900175 | ALLERGAN | Methods of administering dalbavancin for treatment of bacterial infections |
Dec, 2023
(10 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 23, 2019 |
| New Patient Population (NPP) | Jul 22, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | May 23, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.
Dosage: POWDER;INTRAVENOUS
9. List of Fetzima drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8865937 | ALLERGAN | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43879 | ALLERGAN | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Jan, 2026
(2 years from now) | |
| US8481598 | ALLERGAN | Stable dosage forms of levomilnacipran |
Mar, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Oct 7, 2022 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
10. List of Gelnique drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10449173 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(6 years from now) | |
| US9259388 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(6 years from now) | |
| US8920392 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(8 years from now) | |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel; Treatment of overactive bladder by application of oxybutynin chloride gel to skin
Dosage: GEL;TRANSDERMAL
11. List of Gelnique 3% drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7198801 | ALLERGAN | Formulations for transdermal or transmucosal application |
Jun, 2022
(7 months ago) | |
Drugs and Companies using OXYBUTYNIN ingredient
Market Authorisation Date: 07 December, 2011
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
12. List of Lastacaft drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617695 | ALLERGAN | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(4 years from now) | |
| US8664215 | ALLERGAN | Ocular allergy treatments with alcaftadine |
Dec, 2027
(4 years from now) | |
Drugs and Companies using ALCAFTADINE ingredient
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
13. List of Latisse drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8038988 | ALLERGAN | Method of enhancing hair growth |
Aug, 2023
(6 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263054 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(16 days ago) | |
| US8986715 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(16 days ago) | |
| US9226931 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(16 days ago) | |
| US8632760 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(16 days ago) | |
| US8758733 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(16 days ago) | |
| US9216183 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(16 days ago) | |
| US8101161 | ALLERGAN | Method of enhancing hair growth |
May, 2024
(1 year, 3 months from now) | |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of increasing hair growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth; Method of stimulating hair growth; Treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness
Dosage: SOLUTION/DROPS;TOPICAL
14. List of Lexapro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(5 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7420069 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(5 months ago) | |
|
US7420069
(Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(11 days from now) | |
|
US6916941
(Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(11 days from now) | |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
15. List of Linzess drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080526 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
| US7704947 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
| US7745409 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
| US7371727 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
| US7304036 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(11 months from now) | |
| US8933030 | ALLERGAN | Treatments for gastrointestinal disorders |
Feb, 2031
(8 years from now) | |
| US10702576 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(8 years from now) | |
| US10675325 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(8 years from now) | |
| US8802628 | ALLERGAN | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(8 years from now) | |
| US8748573 | ALLERGAN | Formulations comprising linaclotide |
Oct, 2031
(8 years from now) | |
| US9708371 | ALLERGAN | Treatments for gastrointestinal disorders |
Aug, 2033
(10 years from now) | |
Drugs and Companies using LINACLOTIDE ingredient
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.
Dosage: CAPSULE;ORAL
16. List of Lumigan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7851504 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9241918 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8309605 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8586630 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8524777 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US9155716 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8338479 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8772338 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8299118 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8933120 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8933127 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8278353 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 31 August, 2010
Treatment: Method of treating glaucoma or elevated intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; Method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of lowering intraocular pressure; A method of treating a patient with glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
17. List of Namenda Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(6 years from now) | |
|
US8039009
(Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(6 years from now) | |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
18. List of Namzaric drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338485 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8598233 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8168209 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8293794 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8173708 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8362085 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
| US8338486 | ALLERGAN | Methods for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8283379 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8580858 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(2 years from now) | |
| US8329752 | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(2 years from now) | |
|
US8598233
(Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8329752
(Pediatric) | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8283379
(Pediatric) | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(3 years from now) | |
|
US8168209
(Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8173708
(Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8362085
(Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
| US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(6 years from now) | |
|
US8039009
(Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(6 years from now) | |
| US8058291 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(6 years from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
19. List of Ozurdex drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192511 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(22 days ago) | |
| US10702539 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(22 days ago) | |
| US8506987 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(22 days ago) | |
| US8034366 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(22 days ago) | |
| US10076526 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(22 days ago) | |
| US8034370 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(22 days ago) | |
| US6899717 | ALLERGAN | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(8 months from now) | |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); Treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of macular edema; Treatment of uveitis; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex
Dosage: IMPLANT;INTRAVITREAL
20. List of Restasis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629111 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US9248191 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8648048 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8633162 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8642556 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8685930 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
| US8292129 | ALLERGAN | Dispensing device |
Feb, 2031
(8 years from now) | |
| US8561859 | ALLERGAN | Dispensing device |
Apr, 2032
(9 years from now) | |
| US9676525 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(11 years from now) | |
| US9669974 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(11 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
21. List of Saphris drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(3 years from now) | |
| US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7741358
(Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(3 years from now) | |
|
US8022228
(Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(3 years from now) | |
Drugs and Companies using ASENAPINE MALEATE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; Treatment of bipolar disorder and schizophrenia; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or valproate in adults; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes in pediatric patients age 10-17; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes (ages 10 to adult); Method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults
Dosage: TABLET;SUBLINGUAL
22. List of Savella drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6602911 | ALLERGAN | Methods of treating fibromyalgia |
Jan, 2023
(17 days ago) | |
| US7994220 | ALLERGAN | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(6 years from now) | |
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Dosage: TABLET;ORAL
23. List of Teflaro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6417175 | ALLERGAN | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Apr, 2022
(9 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629861 | ALLERGAN | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(7 years from now) | |
| US8247400 | ALLERGAN | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Sep 13, 2022 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Method of treating bacterial infections; Methods for treating bacterial infections
Dosage: POWDER;INTRAVENOUS
24. List of Ubrelvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8912210 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US9499545 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US8754096 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833448 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US10117836 | ALLERGAN | Tablet formulation for CGRP active compounds |
Jan, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with headache, with or without aura in adults
Dosage: TABLET;ORAL
25. List of Viibryd drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7834020 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(7 months ago) | |
| US8673921 | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(7 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236804 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(7 months ago) | |
| US8193195 | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(7 months ago) | |
|
US8673921
(Pediatric) | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(a month ago) | |
|
US8193195
(Pediatric) | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(a month ago) | |
|
US7834020
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(a month ago) | |
|
US8236804
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(a month ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 31, 2023 |
| Pediatric Exclusivity (PED) | Jul 31, 2023 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
26. List of Vraylar drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943621 | ALLERGAN | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(5 years from now) | |
| US7737142 | ALLERGAN | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47350 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(6 years from now) | |
| USRE49110 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | May 24, 2022 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 September, 2015
Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of schizophrenia with cariprazine; Treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic